Tickers

1. Composite Trajectory Verdict

Given TPB's business model as a branded consumer products manufacturer/distributor with significant acquisition-driven growth and working capital intensity, the income statement and cash flow statement carry the most weight for assessing operating trajectory, while the balance sheet reflects financing strategy shifts.

Composite Trajectory: Mixed

The annual income statement shows strong top-line and bottom-line growth (revenue +28% YoY to $463.1M, net income +46% to $58.2M in 2025), but operating margin compressed from 22.4% to 20.6% as SG&A grew 38% versus 28% revenue growth. Operating cash flow declined 14% to $57.4M despite higher net income, driven by a $27.9M unfavorable working capital shift. The balance sheet strengthened materially -- cash rose to $222.8M from $46.2M, the current ratio improved to 5.6x from 4.4x, and debt-to-equity fell to 0.8x from 1.3x -- but this was financed through a $300M debt refinancing at a higher rate (7.625% vs 5.625%) and a $97.5M ATM equity raise, not organic cash generation. Quarterly data is insufficient for trend analysis due to truncated 10-Q filings.

2. Red Flags

• Earnings-cash divergence: 2025 net income attributable to TPB rose 46% to $58.2M (10-K 2025-12-31, Consolidated Statements of Operations) while operating cash flow fell 14% to $57.4M (10-K 2025-12-31, Consolidated Statements of Cash Flows), a $27.9M unfavorable working capital change.
• Margin compression: Operating margin declined from 22.4% (2024) to 20.6% (2025) as SG&A grew 38% ($169.0M vs $122.4M) versus 28% revenue growth (10-K 2025-12-31, MD&A Results of Operations).
• Recurring "non-recurring" SG&A items: Restructuring ($4.6M→$1.2M), ERP/CRM ($0.9M→$0.2M), PMTA ($3.6M→$4.8M), transaction costs ($2.1M→$2.0M), and new items (non-recurring freight $0.8M, legal $0.9M, tariff adjustment $2.0M) appear across multiple years (10-K 2025-12-31, MD&A SG&A breakdown).
• Inventory deposit surge: Other current assets jumped to $60.7M from $34.7M, driven by inventory deposits rising to $28.7M from $6.0M (10-K 2025-12-31, Note 8).
• Accrued liabilities spike: Accrued liabilities rose 75% to $54.6M from $31.1M, including a new $7.4M option agreement liability (10-K 2025-12-31, Note 13).
• Higher-cost debt: Replaced $250M 5.625% 2026 Notes with $300M 7.625% 2032 Notes, increasing annual interest expense by ~$5M (10-K 2025-12-31, Note 14).
• Equity method losses widening: Losses from GWO equity investment grew to $1.2M loss in 2025 from $0.1M income in 2024 (10-K 2025-12-31, Consolidated Statements of Operations).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Revenue grew 28% YoY to $463.1M in 2025 (vs $360.7M in 2024, $325.1M in 2023), driven by Stoker's segment (+69% to $284.6M) led by modern oral products (+$107.7M), while Zig-Zag declined 7% to $178.5M (10-K 2025-12-31, MD&A Net Sales). Gross margin improved to 57.1% from 55.9% on favorable Stoker's mix (10-K 2025-12-31, MD&A Gross Profit). However, operating income grew only 18% to $95.3M as SG&A surged 38% to $169.0M, compressing operating margin to 20.6% from 22.4% (10-K 2025-12-31, MD&A Operating Income). Net income attributable to TPB rose 46% to $58.2M, aided by a $5.5M ERC refund in other income and a lower 18.0% effective tax rate vs 26.1% (10-K 2025-12-31, MD&A Income Tax Expense). Diluted EPS grew to $3.11 from $2.14 (10-K 2025-12-31, Consolidated Statements of Operations). The trajectory is mixed: strong revenue and net income growth offset by margin erosion and reliance on non-operating items.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Operating cash flow declined 14% to $57.4M in 2025 from $67.1M in 2024 (and $66.9M in 2023), despite net income rising 68% to $68.2M (10-K 2025-12-31, Consolidated Statements of Cash Flows). The decline was driven by a $27.9M unfavorable working capital change, primarily from a $25.4M increase in other current assets (largely inventory deposits) and $11.6M inventory build, partially offset by $13.3M accrued liabilities increase (10-K 2025-12-31, Consolidated Statements of Cash Flows). Investing outflows tripled to $31.7M from $10.5M, reflecting $13.5M capex (including modern oral manufacturing), $13.8M investment purchases, $8.0M option agreement payment, and $2.8M non-marketable equity investments (10-K 2025-12-31, Consolidated Statements of Cash Flows). Free cash flow (operating minus capex) fell to $43.8M from $62.3M. Financing flipped to a $148.3M inflow from a $128.3M outflow, driven by $300M 2032 Notes issuance, $97.5M ATM proceeds, and $11.0M Interchange subscription (10-K 2025-12-31, Consolidated Statements of Cash Flows). Quarterly cash flow trends cannot be assessed due to truncated 10-Qs.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total assets grew 55% to $763.8M from $493.4M (10-K 2025-12-31, Consolidated Balance Sheets). Cash surged to $222.8M from $46.2M, funded by financing activities. Current assets rose to $417.2M from $198.2M, with inventories at $108.0M vs $96.3M and other current assets at $60.7M vs $34.7M (10-K 2025-12-31, Consolidated Balance Sheets). Current liabilities increased to $75.0M from $44.8M, but the current ratio improved to 5.6x from 4.4x. Long-term debt rose to $293.6M from $248.6M due to the 2032 Notes issuance, but total equity more than doubled to $372.0M from $190.4M on $97.5M ATM proceeds, $11.0M Interchange subscription, and retained earnings (10-K 2025-12-31, Consolidated Statements of Changes in Stockholders' Equity). Debt-to-equity fell to 0.8x from 1.3x. The ABL facility remains undrawn with $65.8M availability (10-K 2025-12-31, MD&A 2023 ABL Facility). No near-term debt maturities exist (2032 Notes mature 2032). Quarterly balance sheets unavailable from truncated 10-Qs.

6. Data Gaps

• Complete quarterly income statements, cash flow statements, and balance sheets for Q1-Q3 2025 and Q1-Q2 2026 (10-Qs provided are truncated, missing financial statement tables)
• Year-over-year quarterly comparisons for revenue, margins, operating cash flow, and working capital components
• Segment-level quarterly performance (Zig-Zag vs Stoker's) for 2025-2026
• Detailed breakdown of the $28.7M inventory deposits and $7.4M option agreement liability
• Full cash flow statements for interim periods to assess seasonal working capital patterns
• 2026 full-year guidance or updated outlook beyond the February 2026 tariff disclosure in 10-K Note 23